Every two minutes in the world, one woman dies from cervical cancer.¹ 

Cervical cancer is increasingly affecting young women 

aged 30 to 39 and is becoming one of the main causes of female mortality.² 

In Ukraine, the incidence rate of this type of cancer is one of the highest among European countries.³

The root of the evil is that precancerous diseases, such as cervical dysplasia, proceed without symptoms and detection
danger often occurs too late. Regular visits to the gynecologist could definitely make a difference
help, but still they do not solve everything. After all, for even a short break between gynecological examinations, 

a woman can be infected with papillomavirus, herpes, chlamydia, which create conditions for the appearance of dangerous cells.

And only a special female immunity can stand in the way of precancerous disease. 

A unique gynecological program of the International Biotherapy Institute clinical department 

was created to effectively support women's immunity. 

Thanks to natural immune peptides, powerful immune correction will strengthen a woman's immune system and effectively fight off danger.⁴‾⁶
Immune peptides activate special female immunity on the surface of the cervix, and as a result, the woman's immune cells destroy bacteria, 

viruses and dangerous cells that can turn into cancer.

Thanks to the evolutionarily formed properties of immune peptides to react with cell membrane receptors 

and other regulatory molecules, a key process in oncoprevention occurs - unmasking
infected and atypical cells, activation of T-lymphocytes for their inevitable destruction,  involvement macrophages to neutralize toxic residues. 

Therefore, immunocorrection with the help of immune peptides ensures the proper level of the female immunity activity, 

the immediate task of which is to protect against obvious and hidden threats.

                                                                                                                                                                                                                                                  .

References:

1.Beddoe AM. Elimination of cervical cancer: challenges for developing countries. Ecancermedicalscience. 2019 Nov 12;13:975. doi: 10.3332/ecancer.2019.975. PMID: 31921346; PMCID: PMC6946419.

2.Tanaka S, Palmer M, Katanoda K. Trends in cervical cancer incidence and mortality of young and middle adults in Japan. Cancer Sci. 2022 May;113(5):1801-1807. doi: 10.1111/cas.15320. Epub 2022 Mar 15. PMID: 35253327; PMCID: PMC9128164.

3.Tsip. N.P. Cervical cancer in pregnancy^ a modern guideline and a vector for the development of therapeutic approaches. Oncology. 2019, Vol.21 (1). 5 - 9 

4.Zakharenko N  et al. Prospects for the Treatment of Endometriosis: The Effect of Immune Peptides on the Reactivation of Immune Surveillance over Ectopic Endometrial Cells. Journal of Gynecology and Obstetrics. Vol. 8, No. 5, 2020, 148-153

5.Fruitwala S, El-Naccache DW, Chang TL. Multifaceted immune functions of human defensins and underlying mechanisms. Semin Cell Dev Biol. 2019 Apr;88:163-172.

6.Kurchenko A et al., Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology. Int J of Immunology. 2020. Vol. 8 (1):  1-8.